We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the fifteen brokerages that are covering the firm, Ratings reports. One equities ...

Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed ...

Viking Therapeutics stock plunged Thursday on a relatively light earnings report that included mostly incremental updates for its highly anticipated weight-loss drugs. Please watch the video at ...

Citi analyst David Lebowitz maintained a Hold rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $38.00.

We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a ...

State of New Jersey Common Pension Fund D boosted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 8.5% during the fourth quarter, according to its most recent Form 13F filing ...